These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25763753)

  • 1. Bisphosphonate therapy in metastatic carcinoma patients with chronic renal failure: are bisphosphonates an enemy or crony?
    Koseoglu FD; Arslan C
    Support Care Cancer; 2015 Jun; 23(6):1489-91. PubMed ID: 25763753
    [No Abstract]   [Full Text] [Related]  

  • 2. Which bisphosphonate to treat bone metastases?
    Costa L
    Lancet Oncol; 2014 Jan; 15(1):15-6. PubMed ID: 24332513
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prevention and treatment of bisphosphonate-induced jaw bone osteonecrosis. II].
    Fogorv Sz; 2014 Sep; 107(3):106-7. PubMed ID: 25509512
    [No Abstract]   [Full Text] [Related]  

  • 4. Is it feasible to adjust bisphosphonate dose according to bone mineral density value in postmenopausal breast cancer patients with bone metastases?
    Delibasi T; Akkus NI; Altundag O; Pinar T; Altundag K
    Med Hypotheses; 2006; 66(6):1254-5. PubMed ID: 16413688
    [No Abstract]   [Full Text] [Related]  

  • 5. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 6. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.
    Costa L
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate-induced osteonecrosis of the jaws: a case report and literature review.
    Tsai WS; Haghighi K; Placa SJ
    Gen Dent; 2006; 54(3):215-9; quiz 220-2. PubMed ID: 16776417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
    Meattini I; Bruni A; Scotti V; Livi L; De Luca Cardillo C; Galardi A; Cipressi S; Biti G
    J Chemother; 2010 Feb; 22(1):58-62. PubMed ID: 20227995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
    Houston S; Grieve RJ; Hickish T; Percival F; Hamilton E
    J Med Econ; 2010 Mar; 13(1):162-7. PubMed ID: 20136578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.
    Capalbo S; Delia M; Diomede D; Dargenio M; Chiefa A; Favia G; Liso V
    Int J Hematol; 2006 Jun; 83(5):439-42. PubMed ID: 16787865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long interval zoledronic acid use in bone metastases.
    Das M
    Lancet Oncol; 2017 Feb; 18(2):e72. PubMed ID: 28089632
    [No Abstract]   [Full Text] [Related]  

  • 13. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
    Crawford BS; McNulty RM; Kraut EH; Turowski RC
    Cancer Invest; 2009 Dec; 27(10):984-8. PubMed ID: 19909013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taking the lead: sharing best practice in intravenous bisphosphonate use in urological cancers.
    Jensen BT; Dielenseger P; Drudge-Coates L; Flynn K; Hieronymi S; Erik van Muilekom HA; Pieters R; Voss LB
    Eur J Oncol Nurs; 2012 Feb; 16(1):42-53. PubMed ID: 21429796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone-targeted therapies for cancer patients and bone cell biology: where do we stand?
    Berenson JR
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):405-6. PubMed ID: 25319276
    [No Abstract]   [Full Text] [Related]  

  • 16. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review.
    Leite AF; Figueiredo PT; Melo NS; Acevedo AC; Cavalcanti MG; Paula LM; Paula AP; Guerra EN
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jul; 102(1):14-21. PubMed ID: 16831667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates in metastatic bone disease: renal safety matters.
    Body JJ
    Oncologist; 2005; 10 Suppl 1():1-2. PubMed ID: 16264105
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.
    Xie F; Hopkins R; Burke N; Tarride JE; Goeree R
    Hosp Pract (1995); 2012 Apr; 40(2):131-7. PubMed ID: 22615087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
    Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.